vs
Apellis Pharmaceuticals, Inc.（APLS）与HELIX ENERGY SOLUTIONS GROUP INC（HLX）财务数据对比。点击上方公司名可切换其他公司
HELIX ENERGY SOLUTIONS GROUP INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$287.9M vs $199.9M），HELIX ENERGY SOLUTIONS GROUP INC净利率更高（-4.7% vs -29.5%，领先24.8%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -13.8%），HELIX ENERGY SOLUTIONS GROUP INC自由现金流更多（$59.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -11.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Helix Energy Solutions是总部位于美国得克萨斯州休斯顿的油气服务企业，2006年前名为Cal Dive International。该企业是全球离岸油气服务供应商，为新建及在产油气田提供油井干预作业以及遥控潜水器作业服务。
APLS vs HLX — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $287.9M |
| 净利润 | $-59.0M | $-13.4M |
| 毛利率 | — | 3.1% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | -4.7% |
| 营收同比 | -5.9% | -13.8% |
| 净利润同比 | -62.2% | -536.4% |
| 每股收益（稀释后） | $-0.40 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $287.9M | ||
| Q4 25 | $199.9M | $334.2M | ||
| Q3 25 | $458.6M | $377.0M | ||
| Q2 25 | $178.5M | $302.3M | ||
| Q1 25 | $166.8M | $278.1M | ||
| Q4 24 | $212.5M | $355.1M | ||
| Q3 24 | $196.8M | $342.4M | ||
| Q2 24 | $199.7M | $364.8M |
| Q1 26 | — | $-13.4M | ||
| Q4 25 | $-59.0M | $8.3M | ||
| Q3 25 | $215.7M | $22.1M | ||
| Q2 25 | $-42.2M | $-2.6M | ||
| Q1 25 | $-92.2M | $3.1M | ||
| Q4 24 | $-36.4M | $20.1M | ||
| Q3 24 | $-57.4M | $29.5M | ||
| Q2 24 | $-37.7M | $32.3M |
| Q1 26 | — | 3.1% | ||
| Q4 25 | — | 15.2% | ||
| Q3 25 | — | 17.5% | ||
| Q2 25 | — | 4.9% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | — | 20.7% |
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 3.7% | ||
| Q3 25 | 48.7% | 12.7% | ||
| Q2 25 | -18.6% | -1.0% | ||
| Q1 25 | -50.0% | 2.9% | ||
| Q4 24 | -12.3% | 8.7% | ||
| Q3 24 | -24.0% | 13.0% | ||
| Q2 24 | -14.7% | 14.6% |
| Q1 26 | — | -4.7% | ||
| Q4 25 | -29.5% | 2.5% | ||
| Q3 25 | 47.0% | 5.9% | ||
| Q2 25 | -23.6% | -0.9% | ||
| Q1 25 | -55.3% | 1.1% | ||
| Q4 24 | -17.1% | 5.7% | ||
| Q3 24 | -29.2% | 8.6% | ||
| Q2 24 | -18.9% | 8.9% |
| Q1 26 | — | $-0.09 | ||
| Q4 25 | $-0.40 | $0.06 | ||
| Q3 25 | $1.67 | $0.15 | ||
| Q2 25 | $-0.33 | $-0.02 | ||
| Q1 25 | $-0.74 | $0.02 | ||
| Q4 24 | $-0.30 | $0.13 | ||
| Q3 24 | $-0.46 | $0.19 | ||
| Q2 24 | $-0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $501.3M |
| 总债务越低越好 | — | $303.8M |
| 股东权益账面价值 | $370.1M | $1.6B |
| 总资产 | $1.1B | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
| Q1 26 | — | $501.3M | ||
| Q4 25 | $466.2M | $445.2M | ||
| Q3 25 | $479.2M | $338.0M | ||
| Q2 25 | $370.0M | $319.7M | ||
| Q1 25 | $358.4M | $370.0M | ||
| Q4 24 | $411.3M | $368.0M | ||
| Q3 24 | $396.9M | $324.1M | ||
| Q2 24 | $360.1M | $275.1M |
| Q1 26 | — | $303.8M | ||
| Q4 25 | — | $308.0M | ||
| Q3 25 | — | $307.5M | ||
| Q2 25 | — | $311.6M | ||
| Q1 25 | — | $311.1M | ||
| Q4 24 | — | $315.2M | ||
| Q3 24 | — | $314.7M | ||
| Q2 24 | — | $318.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $370.1M | $1.6B | ||
| Q3 25 | $401.2M | $1.6B | ||
| Q2 25 | $156.3M | $1.6B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $1.5B | ||
| Q3 24 | $237.1M | $1.6B | ||
| Q2 24 | $264.3M | $1.5B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $1.1B | $2.6B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $821.4M | $2.7B | ||
| Q1 25 | $807.3M | $2.6B | ||
| Q4 24 | $885.1M | $2.6B | ||
| Q3 24 | $901.9M | $2.7B | ||
| Q2 24 | $904.5M | $2.6B |
| Q1 26 | — | 0.20× | ||
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $61.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $59.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 20.5% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $167.4M |
8季度趋势，按日历期对齐
| Q1 26 | — | $61.8M | ||
| Q4 25 | $-14.2M | $113.2M | ||
| Q3 25 | $108.5M | $24.3M | ||
| Q2 25 | $4.4M | $-17.1M | ||
| Q1 25 | $-53.4M | $16.4M | ||
| Q4 24 | $19.4M | $78.0M | ||
| Q3 24 | $34.1M | $55.7M | ||
| Q2 24 | $-8.3M | $-12.2M |
| Q1 26 | — | $59.0M | ||
| Q4 25 | $-14.3M | $107.5M | ||
| Q3 25 | $108.3M | $22.6M | ||
| Q2 25 | $4.4M | $-21.6M | ||
| Q1 25 | $-53.4M | $12.0M | ||
| Q4 24 | $19.3M | $65.5M | ||
| Q3 24 | — | $52.5M | ||
| Q2 24 | $-8.4M | $-16.2M |
| Q1 26 | — | 20.5% | ||
| Q4 25 | -7.1% | 32.2% | ||
| Q3 25 | 23.6% | 6.0% | ||
| Q2 25 | 2.5% | -7.1% | ||
| Q1 25 | -32.0% | 4.3% | ||
| Q4 24 | 9.1% | 18.4% | ||
| Q3 24 | — | 15.3% | ||
| Q2 24 | -4.2% | -4.4% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.6% | ||
| Q4 24 | 0.0% | 3.5% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.68× | ||
| Q3 25 | 0.50× | 1.10× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.35× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | -0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HLX
暂无分部数据
